INGREZZA® (valbenazine) capsules is a once-daily treatment for adults with tardive dyskinesia and adults with chorea associated with Huntington’s disease.

Actor portrayal

INGREZZA is the only one-capsule, once-daily choice proven to reduce TD and HD chorea severity1
FOR HD CHOREA
Rapid and sustained chorea reductions observed with
INGREZZA as early as Week 2 and through Week 121,2,*
*Change in Total Maximal Chorea score vs placebo from baseline through end of treatment (average of Weeks 10 and 12).

FOR HD CHOREA
Rapid and sustained chorea reductions observed with INGREZZA as early as Week 2 and through Week 121,2,*
REVIEW HD CHOREA EFFICACY*Change in Total Maximal Chorea score vs placebo from baseline through end of treatment (average of Weeks 10 and 12).
UNIQUELY
SELECTIVE
Only INGREZZA exclusively delivers one primary metabolite (+ α) for potent and selective inhibition of VMAT21,3,4,*
EXPLOREPHARMACOLOGY
PROVEN
EFFICACY
INGREZZA 80 mg reduced TD severity in 7 of 10 patients at 6 weeks (post hoc analysis)1,5,†
REVIEW TD EFFICACY
SIMPLE FROM
THE START
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
EXPLORE DOSINGSAVINGS &
SUPPORT
$10 or less out-of-pocket is what most patients pay for INGREZZA6
SEE SUPPORT OPTIONS* | Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and INGREZZA’s primary active metabolite, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes. |
† | Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score. |

CONNECT WITH A
REPRESENTATIVE
Request an office visit from a Neurocrine representative for additional information, patient resources, or samples of INGREZZA.
CONTACT A REPREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Stimming EF, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504.
- Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
- Data on file. Neurocrine Biosciences, Inc.
- Measured by NDC; data on file as of Q2 2023. Neurocrine Biosciences, Inc.
- Data on file as of Q4 2022. Neurocrine Biosciences, Inc.